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The case history is presented of a patient with chronic obstructive pulmonary disease in whom
severe respiratory compromise developed following carbogen inhalation. Clinicians should be
aware of this potentially lethal adverse effect of carbogen in this particular group of patients.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Sudden sensorineural unilateral hearing loss has no known
specific etiologic factor. It has been proposed that inhaled
carbogen, a mixture of 95 percent oxygen and 5 percent
carbon dioxide, will improve oxygenation of inner ear
perilymph and thus improve the likelihood of recovery.1
Case report
A 66-year-old man with a 35-pack-year smoking history,
presented with sudden right ear hearing loss. The patient
had chronic obstructive pulmonary disease (COPD) for 25972 48542321; fax: þ972
t.il (O. Fruchter).
ll rights reserved.years. Spirometry performed several months earlier showed
a FVC ratio (FEV1/FVC) and FEV1 of 39% and 52% of pre-
dicted, respectively. Upon admission the patients was in no
respiratory distress and denied any respiratory symptoms
and arterial blood gas levels on room air were the
following: pH, 7.45; PCO2, 45 mm Hg; and PO2, 82 mm Hg.
The patient was given carbogen inhalation for 30 min,
six times per day. The following day the patient com-
plained of severe shortness of breath. On examination he
appeared somnolent with severe respiratory distress, his
respiratory rate was 30 breaths/min and his oxygen satu-
ration was 80% on ambient air. His chest-X-ray was normal.
Arterial blood gas levels on room air were the following:
pH, 7.22; PCO2, 68.4 mm Hg; and PO2, 55 mm Hg. Carbogen
inhalation was immediately stopped and the patient was
treated by non-invasive-positive-pressure-ventilation bi-
level device improves within 3-h and required no oro-
tracheal intubation and invasive mechanical ventilation.
Hazard for patients with chronic obstructive pulmonary disease from carbogen 257Thepatientwasweanedfromnon-invasiveventilatorysupport
within 24 h and was discharged in good clinical condition.
Discussion
Elevation of end-tidal carbon dioxide concentration (up to
6.9%) and increased arterial oxygen tension have been
reported during carbogen breathing, although no clinical
respiratory compromise has been reported to date in
patients with no prior pulmonary disorders.2
Carbogen inhalation creates a hyperoxicehypercapnic
condition that is poorly tolerated by COPD patients for at
least two reasons. First, supplemental oxygen given to
COPD patients with CO2 retention may result in worsening
respiratory acidosis, an effect that is usually attributed to
the loss of their hypoxic stimulus to breathe.3
Second, the degree of dyspnea in patients with severe
COPD during carbogen inhalation correlates with their
response to increased central drive CO2 stimuli.
4,5
Hence carbogen imposes both an increased hypercapnic
motoneural output to the respiratory system with the
subjective feeling of shortness of breath and hyperoxic
suppression of ventilatory drive that further worsens CO2
retention thus creating a viscous cycle.Carbogen inhalation should be used very cautiously in
COPD patients if at all and monitoring of end-tidal PCO2
should carefully monitor with serial arterial blood gas
measurements, or its administration.
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